These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 38410545)
21. LncRNA MEG3 enhances cisplatin sensitivity in non-small cell lung cancer by regulating miR-21-5p/SOX7 axis. Wang P; Chen D; Ma H; Li Y Onco Targets Ther; 2017; 10():5137-5149. PubMed ID: 29123412 [TBL] [Abstract][Full Text] [Related]
22. MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9. Rao C; Miao X; Zhao G; Zhang C; Shen H; Dong C; Yang M Biomed Pharmacother; 2019 Jun; 114():108662. PubMed ID: 30999114 [TBL] [Abstract][Full Text] [Related]
24. MiR-200c-3p and miR-485-5p overexpression elevates cisplatin sensitivity and suppresses the malignant phenotypes of non-small cell lung cancer cells through targeting RRM2. Liu Y; Zhang Y; Li Q; Xu R; Huang N Thorac Cancer; 2022 Jul; 13(13):1974-1985. PubMed ID: 35599447 [TBL] [Abstract][Full Text] [Related]
25. Long non-coding RNA SNHG1 contributes to cisplatin resistance in non-small cell lung cancer by regulating miR-140-5p/Wnt/β-catenin pathway. Shi SL; Zhang ZH Neoplasma; 2019 Sep; 66(5):756-765. PubMed ID: 31288529 [TBL] [Abstract][Full Text] [Related]
26. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway. Xiao XH; He SY Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431 [TBL] [Abstract][Full Text] [Related]
27. circHUWE1 Exerts an Oncogenic Role in Inducing DDP-Resistant NSCLC Progression Depending on the Regulation of miR-34a-5p/TNFAIP8. Yang X; Sun Q; Song Y; Li W Int J Genomics; 2021; 2021():3997045. PubMed ID: 34901263 [TBL] [Abstract][Full Text] [Related]
28. Mechanism of METTL14-mediated m Gong S; Wang S; Shao M J Mol Med (Berl); 2022 Dec; 100(12):1771-1785. PubMed ID: 36352154 [TBL] [Abstract][Full Text] [Related]
29. Knockdown of long non-coding RNA HOTAIR reverses cisplatin resistance of ovarian cancer cells through inhibiting miR-138-5p-regulated EZH2 and SIRT1. Zhang Y; Ai H; Fan X; Chen S; Wang Y; Liu L Biol Res; 2020 Apr; 53(1):18. PubMed ID: 32349783 [TBL] [Abstract][Full Text] [Related]
30. LncRNA NNT-AS1 contributes to the cisplatin resistance of cervical cancer through NNT-AS1/miR-186/HMGB1 axis. Liu Y; Guo R; Qiao Y; Han L; Liu M Cancer Cell Int; 2020; 20():190. PubMed ID: 32489326 [TBL] [Abstract][Full Text] [Related]
31. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis. Wang L; Shang X; Feng Q Cancer Biol Ther; 2019; 20(3):261-271. PubMed ID: 30481109 [TBL] [Abstract][Full Text] [Related]
32. Long Non-Coding RNA NNT-AS1 Contributes to Cisplatin Resistance via miR-1236-3p/ATG7 Axis in Lung Cancer Cells. Wang H; Guo M; Ding D; Yang F; Chen Z Onco Targets Ther; 2020; 13():3641-3652. PubMed ID: 32431515 [TBL] [Abstract][Full Text] [Related]
33. CircRNA CDR1as/miR-641/HOXA9 pathway regulated stemness contributes to cisplatin resistance in non-small cell lung cancer (NSCLC). Zhao Y; Zheng R; Chen J; Ning D Cancer Cell Int; 2020; 20():289. PubMed ID: 32655321 [TBL] [Abstract][Full Text] [Related]
34. LncRNA FEZF1-AS1 facilitates cisplatin resistance in non-small cell lung cancer through modulating the miR-32-5p-glutaminase axis. Lin W; Wu WC; Liang Z; Zhang JH; Fang SP Am J Cancer Res; 2024; 14(6):3153-3170. PubMed ID: 39005663 [TBL] [Abstract][Full Text] [Related]
35. LncRNA AFAP1-AS1 Supresses miR-139-5p and Promotes Cell Proliferation and Chemotherapy Resistance of Non-small Cell Lung Cancer by Competitively Upregulating RRM2. Huang N; Guo W; Ren K; Li W; Jiang Y; Sun J; Dai W; Zhao W Front Oncol; 2019; 9():1103. PubMed ID: 31696057 [TBL] [Abstract][Full Text] [Related]
36. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells. Ye Y; Zhao L; Li Q; Xi C; Li Y; Li Z Thorac Cancer; 2020 Aug; 11(8):2196-2208. PubMed ID: 32602212 [TBL] [Abstract][Full Text] [Related]
37. Reversal of Chemotherapy Resistance to Cisplatin in NSCLC by miRNA-195-5p via Targeting the Wang H; Sui ZL; Wu XX; Tang P; Zhang HD; Yu ZT Pharmgenomics Pers Med; 2021; 14():497-508. PubMed ID: 33953601 [TBL] [Abstract][Full Text] [Related]
38. Circular RNAcirc_0076305 Promotes Cisplatin (DDP) Resistance of Non-Small Cell Lung Cancer Cells by Regulating Wang X; Wang H; Jiang H; Qiao L; Guo C Cancer Biother Radiopharm; 2023 Jun; 38(5):293-304. PubMed ID: 34339285 [No Abstract] [Full Text] [Related]
39. LncRNA WDFY3-AS2 promotes cisplatin resistance and the cancer stem cell in ovarian cancer by regulating hsa-miR-139-5p/SDC4 axis. Wu Y; Wang T; Xia L; Zhang M Cancer Cell Int; 2021 May; 21(1):284. PubMed ID: 34051810 [TBL] [Abstract][Full Text] [Related]
40. Long noncoding RNA LEF1-AS1 acts as a microRNA-10a-5p regulator to enhance MSI1 expression and promote chemoresistance in hepatocellular carcinoma cells through activating AKT signaling pathway. Gao J; Dai C; Yu X; Yin XB; Zhou F J Cell Biochem; 2021 Jan; 122(1):86-99. PubMed ID: 32786108 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]